https://www.thebodypro.com/category/truvada-pro

Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada)

The Latest

open padlock on blue background
News

This Week in HIV Research: Unlocking Secrets of Engagement in Care

Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.

Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico
Conference Coverage

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

Christoph D. Spinner
Conference Coverage

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

New Option for PrEP: TAF/FTC Is Non-Inferior to TDF/FTC -- Results of Phase 3 DISCOVER Study Img

New Option for PrEP: TAF/FTC Is Non-Inferior to TDF/FTC -- Results of Phase 3 DISCOVER Study

The results from this large study are notable, showing that a new version of PrEP is at least as affective at protecting against HIV infection as the currently approved formulation.

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img
Conference Coverage

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

Promo Image

This Week in HIV Research: Where Are the Cervical Cancer Screens?

Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.

No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study Img
CROI (Conference on Retroviruses and Opportunistic Infections)

No Increase in Adverse Birth Outcomes With Maternal TDF/FTC in U.S. Study

Among pregnant women with HIV in the PROMISE trial, use of TDF/FTC/LPV/r was not associated with increased risk of adverse infant birth outcomes when compared to AZT/3TC/LPV/r or TDF/FTC/ATV/r.

First Generic TDF/FTC Approved in EU Img
News

First Generic TDF/FTC Approved in EU

The European Medicines Agenecy has noted a positive summary of opinion for the first generic combination of tenofovir/emtricitabine (Truvada).

Promo Image
IDWeek

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

Significantly Less BMD Loss With HIV Therapy That Doesn't Contain Tenofovir/Emtricitabine Img
Bone

Significantly Less BMD Loss With HIV Therapy That Doesn't Contain Tenofovir/Emtricitabine

Raltegravir was associated with significantly less bone mineral density (BMD) loss in the hip and lumbar spine than was tenofovir/emtricitabine when used as part of a first-line antiretroviral therapy regimen that contained darunavir boosted with rit...